BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33987857)

  • 21. Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases.
    Woehlecke C; Wittig S; Arndt C; Gruhn B
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):523-9. PubMed ID: 25238704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
    Malagola M; Skert C; Borlenghi E; Chiarini M; Cattaneo C; Morello E; Cancelli V; Cattina F; Cerqui E; Pagani C; Passi A; Ribolla R; Bernardi S; Giustini V; Lamorgese C; Ruggeri G; Imberti L; Caimi L; Russo D; Rossi G
    Cancer Med; 2016 Feb; 5(2):265-74. PubMed ID: 26715369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
    Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
    Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.
    Frairia C; Aydin S; Audisio E; Riera L; Aliberti S; Allione B; Busca A; D'Ardia S; Dellacasa CM; Demurtas A; Evangelista A; Ciccone G; Francia di Celle P; Nicolino B; Stacchini A; Marmont F; Vitolo U
    Leuk Res; 2017 Oct; 61():10-17. PubMed ID: 28846953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
    Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
    Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.
    Sakamoto Y; Mariya Y; Sasaki S; Teshiromori R; Oshikiri T; Segawa M; Ogura K; Akagi T; Kubo K; Kaimori M; Funato T
    Tohoku J Exp Med; 2009 Oct; 219(2):169-76. PubMed ID: 19776535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
    Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
    Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes.
    Pan L; Zhang XJ; Niu ZY; Suo XH; Zhang JY; Yang L; Liu XJ; Qiao SK; Dong ZR; Ohno R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):501-7. PubMed ID: 16800930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
    Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
    Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML.
    Lambert J; Lambert J; Thomas X; Marceau-Renaut A; Micol JB; Renneville A; Clappier E; Hayette S; Récher C; Raffoux E; Pigneux A; Berthon C; Terré C; Celli-Lebras K; Castaigne S; Boissel N; Rousselot P; Preudhomme C; Dombret H; Duployez N
    Blood Adv; 2021 Dec; 5(23):5258-5268. PubMed ID: 34625784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
    Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation.
    Liu H; Wang X; Zhang H; Wang J; Chen Y; Ma T; Shi J; Kang Y; Xi J; Wang M; Zhang M
    Mol Med Rep; 2019 Sep; 20(3):2426-2432. PubMed ID: 31257540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical implication of minimal residue disease monitoring by WT1 gene detection and flow cytometry in myelodysplastic syndrome with allogeneic stem cell transplantation].
    Zhao XS; Mo XD; Hong Y; Chang YJ; Qin YZ; Liu YR; Chen YY; Zhang XH; Xu LP; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):998-1003. PubMed ID: 30612401
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.